• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Pharsight to Present at European Congress of Clinical Microbiology and Infectious Diseases Annual Meeting in Nice, France, on April 2, 2006

Posted on: Friday, 31 March 2006, 06:00 CST

MOUNTAIN VIEW, Calif., March 31 /PRNewswire-FirstCall/ -- Pharsight Corporation (BULLETIN BOARD: PHST) , a leading provider of software and strategic services for optimizing clinical drug development, announced today that Jonathan Kuwabara-Wagg, M.D, Ph.D., Senior Scientist, will present to members of the pharmaceutical and biotechnology industries attending the Annual Meeting of the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) entitled "Best Practices in HIV Drug Development," to be held April 2-4 at the Nice Acropolis in Nice, France. More information on the conference is available at http://www.akm.ch/eccmid2006/ .

"Model-based drug development, which is advocated by the Food and Drug Administration in its Critical Path initiative, goes well beyond PK/PD modeling to support dosing choices," said Shawn O'Connor, Pharsight President and CEO. "This presentation demonstrates the power of integrating a drug-disease model with a commercial model. We believe clients need modeling methods that balance commercial and scientific considerations. For example, integrated scientific-commercial modeling can properly weigh the pros and cons of developing a new once-daily formulation to replace a twice-daily drug. Pharsight's software and services allow clients to complete these types of analyses, allowing them to generate additional value across the entire phase I-IV development portfolio."

Model-Based Development of HIV Compounds

Pharsight has conducted more than 20 HIV projects using model-based drug development techniques over the past eight years, in all development phases and covering critical issues in trial design, dose selection, trial sequencing, and development strategy. This experience covers most mechanisms of action including protease inhibitors, NNRTIs, NRTIs, and novel mechanisms. Typical projects involve integrating relevant sub-models, estimating key parameters from trial data, and simulating candidate trial designs.

About Pharsight Corporation

Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. The company's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.

Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com/ .

Registered Trademarks and Trademarks

Pharsight(R) is a registered trademark of Pharsight Corporation.

Pharsight Corporation

CONTACT: investors, Douglas Sherk, or Jennifer Beugelmans, both at+1-415-896-6820, or media, Steve DiMattia, +1-646-277-8706, all of EVC Group,for Pharsight Corporation

Web site: http://www.pharsight.com/

Source: PRNewswire-FirstCall

More News in this Category